Aspira Women’s Health Receives $10 Million from ARPA-H
AUSTIN, Texas – Aspira Women’s Health Inc. has been recognized as a significant player in the fight for better women’s health diagnostics. Selected by the Advanced Research Projects Agency for Health (ARPA-H), Aspira will benefit from a substantial $10 million funding over the next two years as part of the Sprint for Women’s Health initiative. This funding aims to innovate and tackle critical challenges affecting women’s health, particularly conditions that disproportionately impact them.
Advancing Diagnosis Tools for Endometriosis
The financial support will primarily focus on the development of Aspira's pioneering multi-marker blood test, which is critically designed for the detection of endometriosis, referred to as EndoMDx in its current phase. Aspira will receive milestone-based payments that together sum up to $10 million during the two-year period. Collaborating closely with ARPA-H program managers, the team at Aspira will work diligently to develop and commercially launch this essential non-invasive diagnostic test aimed at identifying endometriosis.
A Competitive Selection Process
In a highly competitive screening that drew over 1,700 submissions, Aspira's selection stands out as a testament to their commitment and expertise in gynecologic disease research. Nicole Sandford, the CEO of Aspira Women’s Health, expressed profound gratitude and pride in the team's hard work throughout the years devoted to advancing endometriosis diagnostics. Their strong foundation in scientific research and operational excellence played a crucial role in their successful bid.
Addressing a Critical Health Crisis
Dr. Sandra Milligan, the company's president, along with Dr. Todd Pappas, Vice President of Research & Development, spearheaded the project proposal and will oversee its execution. They highlighted the urgent need for effective diagnosis and treatment of endometriosis, a chronic gynecologic ailment that affects millions of women in the U.S. alone. Endometriosis significantly impacts the quality of life of those affected, often resulting in severe pain, economic hardship, and social challenges. The current gold standard of diagnosis involves invasive laparoscopic surgery, often leaving women undiagnosed for as long as a decade.
The Economic Impact of Endometriosis
Beyond personal suffering, endometriosis represents a considerable economic burden, costing billions to the American economy in productivity losses and healthcare expenses. As Dr. Milligan noted, "There is a tremendous need for a non-invasive test like ours, and we are excited to move this project forward." This initiative has the potential not only to revolutionize diagnosis but also to significantly alleviate the economic strain associated with this debilitating condition.
Engaging with Investors
To share insights from their ARPA-H presentation and progress on their development pipeline, Aspira will host a virtual Investor Day on a scheduled date. Interested investors have the opportunity to register and gain valuable insights into the company's advancements.
Understanding Aspira Women’s Health
Aspira Women’s Health Inc. is on a mission to innovate in the field of women’s health diagnostics, utilizing AI-powered technology to develop non-invasive tests that can significantly improve the diagnosis of gynecological diseases. Their OvaSuite, which includes OvaWatch and Ova1Plus, provides comprehensive testing for ovarian cancer risk, playing a crucial role for the millions of women facing potential diagnoses annually. This commitment to addressing significant health issues is encapsulated in their ongoing test developments which aim to better identify conditions like endometriosis.
Future Innovations in Diagnostic Testing
As Aspira moves forward in its development pipeline, the focus remains on enhancing its ovarian cancer portfolio. The integration of microRNA and protein biomarkers aims to refine their tests' sensitivity and specificity. Furthermore, the first-ever non-invasive test for endometriomas indicates Aspira's dedication to addressing critical unmet needs in women’s health diagnostics.
Frequently Asked Questions
What is the purpose of the $10 million funding for Aspira?
The funding is aimed at advancing the development of non-invasive diagnostic tools, specifically for the detection of endometriosis.
Who is providing the funding to Aspira Women’s Health?
The funding is provided by the Advanced Research Projects Agency for Health (ARPA-H) through their Sprint for Women’s Health initiative.
What is EndoMDx?
EndoMDx is Aspira's innovative multi-marker blood test designed to aid in the detection of endometriosis.
Why is non-invasive testing important for endometriosis?
Non-invasive testing can significantly reduce the time to diagnosis and eliminate the need for invasive surgeries that many women currently face.
How can investors engage with Aspira about their developments?
Investors can participate in the virtual Investor Day and can register by reaching out to Aspira's investor relations.
